Roche Spin-Off Nimble Therapeutics to Commercialize its Drug Development Technology

 Roche Spin-Off Nimble Therapeutics to Commercialize its Drug Development Technology

Roche’s Tecentriq + Bevacizumab Receive Health Canada’s Approval as 1L Treatment for Unresectable or Metastatic Hepatocellular Carcinoma

Shots:

  • Nimble Therapeutics spins out from Roche to commercialize its chemical synthesis drug discovery & development technology and has received $10M Series A funding from Telegraph Hill Partners
  • The focus of spinning out Nimble Therapeutics is to expand Roche’s chemical synthesis technology by collaborating with other pharma companies to jointly develop drug candidates for multiple therapeutic areas
  • The chemical synthesis technology harnesses the power of photolithography and an extensive library of photoprotected amino acids for synthesis & screening of peptides including scaffolded natural and modified macrocyclic peptidomimetics

Click here to read full press release/ article | Ref: Nimble Therapeutics | Image: Video Blocks

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post